Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer

Matthew A Beldner, Carol A Sherman, Mark R Green, Elizabeth Garrett-Mayer, Uzair Chaudhary, Mario L Meyer, Andrew S Kraft, Alberto J Montero, Matthew A Beldner, Carol A Sherman, Mark R Green, Elizabeth Garrett-Mayer, Uzair Chaudhary, Mario L Meyer, Andrew S Kraft, Alberto J Montero

Abstract

Background: A platinum doublet is the current standard treatment for good performance status patients with advanced non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) with good performance status. However, platinum-based treatment may be associated with significant toxicities, therefore alternative platinum-free combinations should be investigated. Topotecan is a topoisomerase I inhibitor that exerts its cytotoxic effect through stabilization of the topoisomerase I-DNA complex. Preclinical data suggests synergy between topoisomerase I inhibitors and mitotic spindle poisons. Considerable hematologic toxicities have been reported with topotecan dosed for 5 consecutive days in combination with vinorelbine. Therefore, the aim of this study was to evaluate the optimal dosage and the maximal tolerated dose (MTD) of topotecan and vinorelbine in patients with relapsed or refractory non-small cell or small cell lung cancer administered on an alternate dosing schedule.

Methods: From February, 2004 to March, 2007 eighteen patients with advanced or recurrent NSCLC or SCLC previously treated with chemotherapy were enrolled. Patients were heavily pretreated with 22% having received at least 3 prior lines of chemotherapy. Vinorelbine was administered at a fixed dose (20 mg/m2) and topotecan at escalating doses (2, 2.5, 3, 3.5, and 4 mg/m2) on days 1 and 8 every 21 days.

Results: The MTD was not reached in any of the 5 cohorts, with only one dose limiting toxicity (DLT) occurring in cohort 4. Non-hematological toxicities were manageable. One patient had a partial response with four patients (27%) achieving stable disease. The median progression-free and overall survival for all patients, were 2.7 months (95% CI: 1.6, 9.1) and 10.5 months (95% CI: 4.2, 22.7), respectively.

Conclusion: Vinorelbine and topotecan administered on days 1 and 8 every 21 days is well tolerated without any DLT seen with previously investigated topotecan schedules. This doublet provides a potentially active non-platinum containing doublet for the treatment of patients with advanced SCLC and NSCLC. Vinorelbine and topotecan should therefore be investigated in subsequent phase II studies at a dose of 20 mg/m2 and 4 mg/m2, respectively.

Trial registration number: NCT00287963.

Figures

Figure 1
Figure 1
Progression-Free Survival. Median progression free survival for patients in all cohorts was 2.7 months (95% CI, 1.6 to 9.1).
Figure 2
Figure 2
Overall Survival. Median overall survival for patients in all cohorts was 10.5 months (95% CI, 4.2 to 22.7)

References

    1. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–1626.
    1. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist. 2004;9 Suppl 6:25–32. doi: 10.1634/theoncologist.9-90006-25.
    1. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist. 2004;9 Suppl 2:16–23. doi: 10.1634/theoncologist.9-suppl_2-16.
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine. 2002;346:92–98. doi: 10.1056/NEJMoa011954.
    1. Murray N, Turrisi AT., 3rd A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 2006;1:270–278.
    1. Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ. An overview of the clinical pharmacology of topotecan. Seminars in oncology. 1997;24:S5–12-S5-18.
    1. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007;2:526–530.
    1. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090–2096.
    1. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092. doi: 10.1200/JCO.2006.08.3998.
    1. Shah C, Ready N, Perry M, Kirshner J, Gajra A, Neuman N, Garziano S. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2007;57:84–88.
    1. von Pawel J. The role of topotecan in treating small cell lung cancer: second-line treatment. Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 4:S3–8.
    1. Herzog TJ. Clinical experience with topotecan in relapsed ovarian cancer. Gynecologic oncology. 2003;90:S3–7. doi: 10.1016/S0090-8258(03)00467-0.
    1. Armstrong D, O'Reilly S. Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity. Oncologist. 1998;3:4–10.
    1. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667.
    1. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecologic oncology. 2001;83:394–399. doi: 10.1006/gyno.2001.6435.
    1. Tan BR, Read W, Bergeron K, Fracasso PM, Govindan R. Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors. 2004. p. 7344.
    1. Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De Placido S, Gallo C, Monfardini S, Bianco AR. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol. 1998;16:1414–1419.
    1. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, Gozzelino F, Planting A, van Zandwijk N. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29A:1720–1722. doi: 10.1016/0959-8049(93)90112-S.
    1. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459–2465.
    1. Wozniak AJ. Single-agent vinorelbine in the treatment of non-small cell lung cancer. Seminars in oncology. 1999;26:62–6; discussion 71-2.
    1. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer chemotherapy and pharmacology. 2001;48:188–196. doi: 10.1007/s002800100327.
    1. Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044–2051. doi: 10.1200/JCO.2005.03.3332.
    1. Frasci G, Nicolella G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Natale M, Piantedosi F, Russo A, Palmeri S, Comella G, Panza N. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. British journal of cancer. 2001;84:1166–1171. doi: 10.1054/bjoc.2001.1741.
    1. Lorusso V, Gebbia V, Spada M, Guida M, Cassano G, Brunetti C, Germano D, Nettis G, Izzi G, Galetta D, Giampaglia M, Silvestris N, Colucci G. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncology reports. 2005;14:1547–1551.
    1. Perez-Soler R. Topotecan in the treatment of non-small cell lung cancer. Seminars in oncology. 1997;24:S20–34-S20-41.
    1. Pujol JL, von Pawel J, Tumolo S, Martoni A, Hearn S, Fields SZ, Ross G. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Oncology. 2001;61 Suppl 1:47–54. doi: 10.1159/000055392.
    1. Seifart U, Fink T, Schade-Brittinger C, Hans K, Mueller C, Koschel G, Schroeder H, Lorenz R, Dethling J, Wolf M. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol. 2007;18:104–109. doi: 10.1093/annonc/mdl353.
    1. Hanna NH, Gordon MS, Fife K, Sandler AB. Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies. American journal of clinical oncology. 2002;25:337–339. doi: 10.1097/00000421-200208000-00002.
    1. Stupp R, Bodmer A, Duvoisin B, Bauer J, Perey L, Bakr M, Ketterer N, Leyvraz S. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology. 2001;61 Suppl 1:35–41. doi: 10.1159/000055390.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj